Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Lonza has agreed to manufacture the biologic drug Remsima for Celltrion at its facilities in Singapore to meet growing demand in North America and Europe. Remsima is a biosimilar monoclonal antibody medication approved in Europe and the US for treating a variety of autoimmune diseases. Separately, a joint venture formed earlier this year between Lonza and the Danish foods firm Chr. Hansen to manufacture live therapeutic microbes for the emerging microbiome drug sector has received approval from regulators. Named BacThera, the partnership is upgrading facilities in Horsholm, Denmark, and Basel, Switzerland, to serve preclinical-to-Phase II projects.
This article has been sent to the following recipient: